Vanguard Real Estate Index Fund ETF vs Viatris Inc — how do they compare? Vanguard Real Estate Index Fund ETF trades at $95.14, while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc pays a 2.89% dividend while Vanguard Real Estate Index Fund ETF pays none, and Viatris Inc is trading nearer its 52-week high, Vanguard Real Estate Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| VNQ | VTRS | |
|---|---|---|
52-Week High | $100.95 | $17.86 |
52-Week Low | $87.00 | $9.49 |
Market Cap | — | $19.09B |
Sector | — | Health |
Enterprise Value | — | $31.21B |
Dividend Yield | — | 2.89% |
Signals from Pluang's Aura AI — not financial advice
VNQ trades at $95.92, down 0.1% on the day, with technical indicators showing a bearish trend as moving averages signal selling pressure while oscillators remain neutral. The ETF faces headwinds from elevated interest rates impacting real estate valuations, though some analysts see mispricing opportunities in quality REITs during this downturn. Recent institutional selling activity and mixed media sentiment reflect ongoing sector challenges.
The outlook remains cautious as high rates pressure REIT valuations, but selective opportunities exist in digital infrastructure and quality names. Key risks include prolonged high interest rates, economic slowdowns affecting property demand, and competition from alternative income ETFs. Investors should focus on REITs with strong fundamentals and growth potential in evolving sectors like AI infrastructure.
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
Trailing returns across standard periods
Latest headlines on both assets
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →